Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.

about

Therapeutics for filovirus infection: traditional approaches and progress towards in silico drug design.

P2860

Q34371001-C408FAE4-5B16-4CBE-AF6E-753AE1DA37AB

P2860

Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.

Item

http://www.wikidata.org/entity/Q54533328

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Imatinib and beyond--targeting ...... myeloproliferative disorders.

@en

Imatinib and beyond--targeting ...... myeloproliferative disorders.

@nl

type

Item

label

Imatinib and beyond--targeting ...... myeloproliferative disorders.

@en

Imatinib and beyond--targeting ...... myeloproliferative disorders.

@nl

prefLabel

Imatinib and beyond--targeting ...... myeloproliferative disorders.

@en

Imatinib and beyond--targeting ...... myeloproliferative disorders.

@nl

P1476

Imatinib and beyond--targeting ...... myeloproliferative disorders.

@en

P2093

Andreas Reiter

http://www.w3.org/2001/XMLSchema#string

Thomas Ernst

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of the Philadelphia chromosome: a personal perspective

Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

P304

34-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000334824

http://www.w3.org/2001/XMLSchema#string

P478

35 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Hochhaus

Paul La Rosée

P577

2012-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22286586

http://www.w3.org/2001/XMLSchema#string

Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.

about

P2860

P2860

Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698